Stanley Joewono is an Indonesia social media influencer and exercise enthusiast. Diagnosed with thalassemia at just 8 months ...

A next generation Snap Cartridge, part of the Gazelle™ S-10B Hb Variant Test Multipack, will simplify sample preparation so ...

Members of the NIH’s recently reconstituted scientific management review board had strong reactions to congressional ...

These three emerging technology leaders are pioneering quantum computing, gene editing, and electric aviation.

Gene therapy that alters hemoglobin genes may be an answer to curing sickle cell disease (SCD) and beta thalassemia. When the normal DNA sequence in an individual changes or mutates it can cause ...

Beam Therapeutics enrolls 35 patients in BEACON trial for BEAM-101 in sickle cell disease, with promising early safety and ...

Crispr has already secured a historic first approval for a CRISPR/Cas9 drug and has several more potential blockbuster ...

Beta-thalassemia is a rare blood disorder caused by a genetic defect in hemoglobin. Several manufacturers are developing novel treatments for the disease, including Vertex, which has partnered ...

A live webcast of the fireside chat will be available on the "Events & Presentations" page in the Investors section of the Company's website at https://crisprtx.gcs-web.com/events. A replay of the ...

The 12-month price targets, analyzed by analysts, offer insights with an average target of $4.43, a high estimate of $10.00, ...

Editas Medicine EDIT incurred a loss of 75 cents per share in the third quarter of 2024, narrower than the Zacks Consensus ...

SOMERVILLE, Mass., November 14, 2024--bluebird bio, Inc. (NASDAQ: BLUE) ("bluebird bio" or the "Company") today reported third quarter results and business highlights for the quarter ended September ...